Cytosorbents (NASDAQ:CTSO) Stock Crosses Above 200 Day Moving Average - What's Next?

Cytosorbents Corporation (NASDAQ:CTSO - Get Free Report)'s share price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.02 and traded as high as $1.16. Cytosorbents shares last traded at $1.03, with a volume of 119,178 shares.

Analyst Ratings Changes

Several equities analysts have commented on the stock. HC Wainwright reissued a "neutral" rating and set a $1.00 target price on shares of Cytosorbents in a research report on Thursday, May 15th. D. Boral Capital reissued a "buy" rating and set a $10.00 target price on shares of Cytosorbents in a research report on Wednesday, June 25th. Finally, Wall Street Zen started coverage on shares of Cytosorbents in a research report on Wednesday, May 21st. They set a "hold" rating on the stock.

Cytosorbents Price Performance

The company has a current ratio of 2.61, a quick ratio of 2.30 and a debt-to-equity ratio of 0.98. The company has a market cap of $64.49 million, a P/E ratio of -3.68 and a beta of 1.19. The business's fifty day moving average is $1.01 and its 200 day moving average is $1.02.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The medical research company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. The company had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.01 million. Cytosorbents had a negative net margin of 41.77% and a negative return on equity of 105.04%. As a group, sell-side analysts anticipate that Cytosorbents Corporation will post -0.3 EPS for the current year.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds and other institutional investors have recently bought and sold shares of CTSO. Avenir Corp raised its holdings in Cytosorbents by 63.1% during the 1st quarter. Avenir Corp now owns 5,044,918 shares of the medical research company's stock valued at $5,045,000 after acquiring an additional 1,950,972 shares during the period. CM Management LLC raised its holdings in Cytosorbents by 36.3% during the 1st quarter. CM Management LLC now owns 954,076 shares of the medical research company's stock valued at $954,000 after acquiring an additional 254,076 shares during the period. Skylands Capital LLC raised its holdings in Cytosorbents by 7.9% during the 1st quarter. Skylands Capital LLC now owns 3,002,702 shares of the medical research company's stock valued at $3,003,000 after acquiring an additional 221,080 shares during the period. Raymond James Financial Inc. bought a new stake in Cytosorbents during the 4th quarter valued at $99,000. Finally, Key Client Fiduciary Advisors LLC raised its holdings in Cytosorbents by 127.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock valued at $78,000 after acquiring an additional 43,900 shares during the period. Institutional investors own 32.87% of the company's stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.